Memorial Hospital Research Laboratories
The James Young Lab
Our lab studies human dendritic cells, which are critical to the onset of cellular immunity. Dendritic cells also provide an important link between innate and adaptive immune responses. Our work is broadly informed by issues in clinical transplantation and tumor immunology.
Ratzinger G, Baggers J, de Cos MA, Yuan J, Reagan JL, Dao T, Munz C, Heller G, Young JW. Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells. J Immunol. 2004;173:2780-2791.
Munz C, Dao T, Ferlazzo G, de Cos MA, Goodman K, Young JW. Mature myeloid dendritic cell subsets have distinct roles for activation and viability of circulating human natural killer cells. Blood. 2005 Jan 1;105(1):266-73.
Boruchov AM, Heller G, Veri M-C, Bonvini E, Ravetch JV, Young JW. Activating and inhibitory IgG Fc receptors mediate opposing functions on human dendritic cells. J.Clin.Invest. 2005, 115: 2914-2923 (see also J.Clin.Invest. 2005, 115: 2585)
Yuan J, Latouche J-B, Hodges J, Houghton AN, Heller G, Sadelain M, Riviere I, Young JW. Langerhans-type dendritic cells genetically modified to express full-length antigen optimally stimulate CTLs in a CD4-dependent manner. J.Immunol. 2006, 176: 2357-2365.
James W. Young, MD
- Physician-scientist James Young studies innate and adaptive immunity against tumors and viruses stimulated by human dendritic cells.
- MD, Vanderbilt University
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James W. Young discloses the following relationships and financial interests:
Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.